A Study of Orforglipron (LY3502970) to Compare a Single Capsule and Multiple Capsules in Healthy Participants

NCT06692348 · Completed

Last updated 2026-05-28

This clinical trial is testing how the body absorbs a single capsule versus multiple capsules of the drug Orforglipron in healthy participants.

Status Completed The study has finished.

Phase Phase 1 Checks safety and dosing in a small group.

Type Interventional (clinical trial)

Design Randomized, open-label (no blinding) basic-science study

Participants 86 people

Who can join Ages 18–65 · all sexes Healthy volunteers accepted.

Timeline Started 2024-12 · est. completion 2025-06

Where 3 sites · Japan

What this study is testing ClinicalTrials.gov NCT06692348 ↗

Description as written by the study sponsor.

The main purpose of this study is to assess and compare a single capsule and multiple capsules of Orforglipron based on the amount that gets into the blood stream and how long it takes the body to get rid of it, when given to healthy participants under fasted and fed conditions. How the body handles and eliminates the study drug after meals and on an empty stomach will be measured. Information about any adverse effects experienced will be collected and the safety and tolerability of Orforglipron will also be evaluated. The study will last approximately 21 weeks, including a screening period.

Treatments tested

Orforglipron also known as LY3502970 Drug

Administered orally

Main thing measured	Pharmacokinetics (PK): Steady-state Area Under the Concentration Versus Time Curve (AUC) of Orforglipron (Fasted State)
Sponsor	Eli Lilly and Company
Conditions studied	Healthy
GLP-1 drugs	orforglipron

Full protocol, eligibility, and contacts on ClinicalTrials.gov NCT06692348 ↗